• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Integration of Trastuzumab, with or without Pertuzumab, into Perioperative Chemotherapy of HER2- Positive Stomach Cancer: The INNOVATION Trial (EORTC-1203-GITCG).

出版信息

Oncol Res Treat. 2016;39(3):153-4; discussion 155. doi: 10.1159/000444702.

DOI:10.1159/000444702
PMID:27486629
Abstract
摘要

相似文献

1
Integration of Trastuzumab, with or without Pertuzumab, into Perioperative Chemotherapy of HER2- Positive Stomach Cancer: The INNOVATION Trial (EORTC-1203-GITCG).将曲妥珠单抗（无论是否联合帕妥珠单抗）纳入HER2阳性胃癌围手术期化疗：INNOVATION试验（欧洲癌症研究与治疗组织-1203-胃肠道肿瘤协作组）
Oncol Res Treat. 2016;39(3):153-4; discussion 155. doi: 10.1159/000444702.
2
EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.EORTC-1203-GITCG - “创新”试验：曲妥珠单抗单药与曲妥珠单抗加帕妥珠单抗联合化疗在 HER2 阳性胃和胃食管交界处腺癌围手术期治疗中的疗效对比：EORTC 胃肠道肿瘤研究组、韩国癌症研究组和荷兰上消化道肿瘤组的一项随机 II 期分组试验。
BMC Cancer. 2019 May 24;19(1):494. doi: 10.1186/s12885-019-5675-4.
3
Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma?曲妥珠单抗联合化疗在 2 neu 阳性局部胃腺癌围手术期治疗中有优势吗？
World J Surg Oncol. 2011 Sep 28;9:112. doi: 10.1186/1477-7819-9-112.
4
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.局部晚期、炎症性或早期 HER2 阳性乳腺癌患者新辅助帕妥珠单抗和曲妥珠单抗的 5 年分析（NeoSphere）：一项多中心、开放性标签、2 期随机试验。
Lancet Oncol. 2016 Jun;17(6):791-800. doi: 10.1016/S1470-2045(16)00163-7. Epub 2016 May 11.
5
[A case of curative surgery for HER2-positive gastric cancer after chemotherapy using paclitaxel combined with trastuzumab].[1例经紫杉醇联合曲妥珠单抗化疗后行HER2阳性胃癌根治性手术的病例]
Gan To Kagaku Ryoho. 2014 Nov;41(12):2302-4.
6
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.新辅助帕妥珠单抗和曲妥珠单抗治疗局部晚期、炎症型或早期 HER2 阳性乳腺癌的疗效和安全性（NeoSphere）：一项随机、多中心、开放性、Ⅱ期临床试验。
Lancet Oncol. 2012 Jan;13(1):25-32. doi: 10.1016/S1470-2045(11)70336-9. Epub 2011 Dec 6.
7
Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.分析HER家族（HER1-4）表达作为帕妥珠单抗、曲妥珠单抗和多西他赛联合治疗晚期HER2阳性乳腺癌的生物标志物
Anticancer Res. 2018 Apr;38(4):2285-2294. doi: 10.21873/anticanres.12473.
8
First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer.厄瑞布林联合曲妥珠单抗和帕妥珠单抗治疗晚期 HER2 阳性乳腺癌的首次报告。
Breast. 2017 Oct;35:78-84. doi: 10.1016/j.breast.2017.06.015. Epub 2017 Jun 27.
9
Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.曲妥珠单抗为基础的治疗后帕妥珠单抗单药治疗及后续曲妥珠单抗再引入：晚期人表皮生长因子受体 2 阳性乳腺癌患者的疗效和耐受性。
J Clin Oncol. 2012 May 10;30(14):1594-600. doi: 10.1200/JCO.2011.37.4207. Epub 2012 Mar 5.
10
HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation.接受曲妥珠单抗治疗的 HER2 阳性患者与 HER2 阴性晚期胃癌患者具有可比的预后：一项前瞻性队列观察。
Int J Cancer. 2014 May 15;134(10):2468-77. doi: 10.1002/ijc.28559. Epub 2013 Nov 8.

引用本文的文献

1
Impact of HER2 status in resected gastric or gastroesophageal junction adenocarcinoma in a Western population.HER2状态对西方人群中切除的胃或胃食管交界腺癌的影响。
Ecancermedicalscience. 2020 Mar 24;14:1020. doi: 10.3332/ecancer.2020.1020. eCollection 2020.
2
Multimodal Treatment Strategies in Esophagogastric Junction Cancer: a Western Perspective.食管胃交界部癌的多模式治疗策略：西方视角
J Gastric Cancer. 2019 Jun;19(2):148-156. doi: 10.5230/jgc.2019.19.e19. Epub 2019 May 24.
3
The downstaging approach to irresectable oesophageal and gastric cancer: a single centre experience.
不可切除食管癌和胃癌的降期治疗方法：单中心经验
J Gastrointest Oncol. 2019 Jun;10(3):499-505. doi: 10.21037/jgo.2019.01.32.